




# Corporate Presentation

May 5, 2021

NON-BINDING TRANSLATION – The following presentation is a free translation of Company's presentation in Hebrew published on the TASE. In the event of inconsistency between this version and the Hebrew one, the Hebrew language version shall prevail.



# Forward Looking Statement

- This presentation was prepared by BioLight Life Sciences Ltd. ("BioLight") and contains only concise information. It does not include a detailed and/or complete information regarding BioLight, its subsidiaries and affiliates (together the "Company"), its activities or forecasts regarding its activities, and, does not purport to encompass or contain all the information that is required and/or may be relevant for the purpose of making any decision and/or resolution with respect to any investment in the Company's securities and is not intended to replace the requirement to review the full Company's documents and/or any publication regarding the Company which is published and/or will be published in the future.
- The presentation includes forward-looking information as defined in the Israeli Securities Law 1968, which is based, to a large extent, on current and subjective expectations and assessments of BioLight's forecasts, estimates and other information relating to future events and matters, all or some of which are uncertain and beyond BioLight's control. Additional facts and data that served as the basis for information hereof are based on facts and data regarding the current state of BioLight, the Company and its businesses, facts and data regarding the current state of the field of activity in which BioLight operates, and facts and macro economic data, all as known to BioLight at the date of this presentation, including public data and statistical publications published by various entities and authorities, whose contents have not been independently examined by BioLight and therefore BioLight is not responsible for their correctness.
- This Presentation does not constitute an offer, an invitation nor a solicitation to purchase the Company's securities and does not constitute a recommendation or opinion or a substitute for an investor's discretion.
- The asset & investment summary table as of December 31, 2020 ("Table") which is part of this Presentation is based on non-GAAP financial presentation. The Company believes that the summary detailed in the Table, together with the explanations, may assist to comprehend the status of the Company's assets and constitutes additional and complete information alongside the detailed information regarding these assets presented in the financial statements which are prepared according to generally accepted accounting principals. It should be emphasized that the information contained in the Table is not a substitute for the information contained in the Company's financial statements.

## Prevalence of eye diseases is constantly increasing



**340M** Dry eye syndrome



**146M** Diabetic retinopathy



**76M** Glaucoma

These statistics are a small representation of a variety of diseases from which billions suffer

## Today's Challenges and Unmet Needs

- Aging population
- Prevalence of eye disease rising
- Insufficient eye doctors in relation to population growth
- Fear of losing eye sight (blindness)


# 75%

of global vision impairment  
can be avoided

## Tomorrow's Solutions

- Early detection
- Better and personalized drugs
- Improved devices for procedure and implants
- Usage of digital health for remote diagnosis and accurate treatment

# Holding Chart



\* The final stage of the acquisition of IOptima is expected to occur in the second quarter of 2021



# BioLight's Activities in Ophthalmology (Subsidiaries)



Develops advance procedure using a laser device for less invasive glaucoma surgery procedures

**SOLD**

## Status

Acquired by a large Chinese company, Chengdu KangHong Pharmaceuticals Co. The final stage of the acquisition is expected to generate approximately \$5.7 million in gross revenue for BioLight



Develops the TeaRx™ technology, designed to diagnose front of the eye diseases, by examining and analyzing the composition of tear fluid samples; its first indication is designed for detection, personalization & follow up for dry eye syndrome

**82%**

## Status

- Preparing for a large scale clinical trial for the purpose of assessing a potential commercial cooperation with a big pharmaceuticals company.
- Signed strategic Investment of USD 4 million at a post money valuation of USD 18.25 million and a worldwide commercial manufacturing agreement
- Received positive results in the fourth clinical trial of the TeaRx™ technology



Develops a sub- conjunctiva implant (EYE-D) for the slow and controlled release of an active substance (API) for the treatment of glaucoma

**97%**

## Status

Following the success of phase I/IIa of the U.S. trial (safety and initial efficacy), completes the upgrade of the Eye-D product and its proprietary inserter and is seeking a partner to fund its next clinical trial

# BioLight's Activities in Ophthalmology (Subsidiaries-cont.)



Develops droplet formulas for the delivery of oily molecules to the front of the eye, for a variety of diseases

90%

## Status

Signed a Term Sheet with a European manufacturer for the engagement in a manufacturing and CE registration of its Ocular D product and is preparing for the possible launch of the product in Europe



Develops drugs to treat eye diseases through an innovative technology platform that improves the delivery of eye drops based on nano-structures

41%

## Status

Preparing for and examining a human clinical trial for high-dose CysA; Examining expanding its pipeline of products in development to products designated to the back of the eye, focusing mainly on diseases that harm the retina

# BioLight's Investments in Ophthalmology (affiliates)



Develops an innovative surgical procedure for the treatment of the Glaucoma

5%

## Status

Obtained CE approval for marketing the product in Europe and approval to market it in Israel and signed its first distribution agreements in Europe and Israel  
Awaits for final results of clinical trial following one year follow-up of patients




Develops an innovative product, the TRS01, based on the technological platform for the treatment of inflammatory ocular diseases that may lead to blindness

4.5%

## Status

Successfully Completed clinical trial carried out in US as part of phase I/IIa to assess its safety and effectiveness in treating Uveitis in non-infected or inflamed eyes of patients suffering from Glaucoma



BELKIN  
LASER

Develops clinic laser device to enable glaucoma patients to receive short & effective laser treatments as first line treatment of disease

4%

## Status

Is in the advanced stage of recruiting patients for its multi-central clinical trial (in England, Italy and Israel)



# BioLight's Investments in Ophthalmology (affiliates)



**A EYE Health**

Develops artificial intelligence (AI) solutions for a variety of retinal diseases

5%

## Status

Is in the advanced stage of a clinical trial in the U.S., in order to obtain FDA approval for one of the its products in the field of artificial automatic screening of retinopathic diabetics complications

The next thing...



The Company seeks to expand its portfolio of technologies and products in the field of ophthalmology, with emphasis on ophthalmic companies that combine digital health, with priority to companies relatively close to revenues stage

# BioLight's assets & investments summary as of December 31, 2020 (K NIS)

The data in the table below are Non-GAAP

Cash

**31,149**

As of December 31, 2020 (1)

Cash  
receivable

**18,326**

Expected proceeds from the fourth closing of IOptima sale, expected to be on the second quarter of 2021, translated to NIS using exchange rate as of December 31, 2020

DiagnosTear

**44,338**

Estimated based on BioLight's holdings rate, per-money, in Elcam medical transaction

Tradable stocks  
(NXTG)

**1,976**

Based on the share price traded on TASE as of December 31, 2020 (2)

Sub-total

**95,789**

Investment in  
companies

**44,430**

Investments in ViSci, Lipicare, Belkin Laser, Tarsier, Sanoculis and OphRx (cost basis only)

Total

**140,219**

(1) Including short term deposits and approximately NIS 4 million in DiagnosTear

(2) Sold in January 2021 for NIS 1.9 million

\*\* The above summary does not include the investment in Aeye Health on March 2021 in the amount of approximately NIS 3.3 million

# Highly Experienced Managing Team



**Israel Makov, Chairman of the Board**

Serves as the Chairman of the Board Sun Pharmaceuticals, Chairman of the Board of Nexstage Therapeutics Ltd. and Quantalx Neuroscience. Makov was former President & CEO of Teva Pharmaceuticals. In said capacity Makov led Teva's global expansion. Prior to joining Teva, Makov led companies from a variety of industries such as founding the first biotechnology company in Israel, InterPharm, and serving as chairman of Given Imaging and Chairman of the Board of Netafim.



**Yaacov Michlin, CEO**

Serves as the Co-Chairman (Life Sciences) of the IATI. Previously, the CEO & President of Brainsway, leading it to a successful NASDAQ IPO. Prior to Brainsway, Mr. Michlin was the CEO & President of Yissum and founder and chairman of Integra Holdings (a successful early stage VC).



**Yiftach Biel, CFO**


Served as BioLight corporate controller for five years prior to his appointment as CFO and as Previously, the finance manager of Delek Global Real Estate, an international real estate company with asset portfolio of billions NIS in Europe, Canada and Israel. Holds B.A. in Business management and a certified Public Accountant



**Karin Gurevitz, Vice President**

**General Counsel & Company Secretary**  
Previously served as Chief Legal Counsel, Company Secretary and IPO manager in several traded and private multi-national companies, including Tahal Group and Polar Investments Group.  
  
Holds LLB in Law and MBA from Tel Aviv University

# Main Shareholders [TASE: BOLT]





# THANK YOU

Email: [Biolight@bio-light.co.il](mailto:Biolight@bio-light.co.il)

Company web site: <https://bio-light.co.il/>